These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15768380)

  • 1. A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
    Bomgaars L; Kerr J; Berg S; Kuttesch J; Klenke R; Blaney SM
    Pediatr Blood Cancer; 2006 Jan; 46(1):50-5. PubMed ID: 15768380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
    Blaney S; Berg SL; Pratt C; Weitman S; Sullivan J; Luchtman-Jones L; Bernstein M
    Clin Cancer Res; 2001 Jan; 7(1):32-7. PubMed ID: 11205914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
    Vassal G; Doz F; Frappaz D; Imadalou K; Sicard E; Santos A; O'Quigley J; Germa C; Risse ML; Mignard D; Pein F
    J Clin Oncol; 2003 Oct; 21(20):3844-52. PubMed ID: 14551303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
    Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
    Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
    Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R
    Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
    Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
    Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
    Furman WL; Stewart CF; Poquette CA; Pratt CB; Santana VM; Zamboni WC; Bowman LC; Ma MK; Hoffer FA; Meyer WH; Pappo AS; Walter AW; Houghton PJ
    J Clin Oncol; 1999 Jun; 17(6):1815-24. PubMed ID: 10561220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
    J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
    Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
    McGregor LM; Stewart CF; Crews KR; Tagen M; Wozniak A; Wu J; McCarville MB; Navid F; Santana VM; Houghton PJ; Furman WL; Rodriguez-Galindo C
    Pediatr Blood Cancer; 2012 Mar; 58(3):372-9. PubMed ID: 21509928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
    Furman WL; Crews KR; Billups C; Wu J; Gajjar AJ; Daw NC; Patrick CC; Rodriguez-Galindo C; Stewart CF; Dome JS; Panetta JC; Houghton PJ; Santana VM
    J Clin Oncol; 2006 Feb; 24(4):563-70. PubMed ID: 16446328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
    Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
    Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
    Furman WL; Navid F; Daw NC; McCarville MB; McGregor LM; Spunt SL; Rodriguez-Galindo C; Panetta JC; Crews KR; Wu J; Gajjar AJ; Houghton PJ; Santana VM; Stewart CF
    J Clin Oncol; 2009 Sep; 27(27):4599-604. PubMed ID: 19687340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
    Infante JR; Keedy VL; Jones SF; Zamboni WC; Chan E; Bendell JC; Lee W; Wu H; Ikeda S; Kodaira H; Rothenberg ML; Burris HA
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):699-705. PubMed ID: 22941375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
    Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.